Related by context. All words. (Click for frequent words.) 77 tolerability profile 77 tolerability 77 pharmacokinetics 76 pharmacodynamic profile 72 pharmacokinetic 71 pharmacokinetic profiles 71 pharmacokinetic properties 71 pharmacodynamic 70 oral bioavailability 70 analgesic efficacy 70 pharmacokinetics PK 70 pharmacodynamics 70 antiviral activity 68 safety tolerability pharmacokinetics 68 favorable pharmacokinetic profile 68 immunogenicity 68 safety tolerability pharmacokinetic 68 pharmacodynamic properties 68 bronchodilation 68 safety tolerability 67 pharmacokinetic characteristics 67 tolerated dose MTD 67 pharmacodynamic effects 67 dosing regimen 67 pharmacokinetic PK profile 67 pharmacodynamic PD 67 antitumor activity 67 antiviral efficacy 66 dosing regimens 66 pharmacokinetic parameters 66 anti leukemic 66 efficacy 66 orally bioavailable 66 ORMD 65 pharmacodynamics PD 65 Azedra 65 ascending doses 65 pharmacokinetic PK 65 oral prodrug 65 Sym# 65 plasma concentrations 65 dosage regimens 64 efficacy tolerability 64 mcg dose 64 #mg dose [001] 64 administered subcutaneously 64 administered orally 64 oral dosing 64 RDEA# 64 subcutaneously administered 64 edoxaban 64 Phase 1b trial 64 GLYX 64 maximally tolerated dose 64 preclinically 63 teriflunomide 63 ENMD # 63 active comparator 63 NGX# 63 subcutaneous formulation 63 Cmax 63 rHuPH# 63 dose escalation trial 63 subcutaneous SC 63 tolerability profiles 63 teduglutide 63 favorable tolerability 63 PRTX 63 polymerase inhibitor 63 GFT# 63 neuroprotective properties 63 LY# [002] 63 tanespimycin 62 single ascending dose 62 dose limiting toxicities 62 rFIXFc 62 active metabolite 62 CIMZIA TM 62 SRT# [003] 62 systemically administered 62 PRT# 62 dosing 62 dose cohorts 62 investigational oral 62 Triolex 62 mg dose 62 antiviral potency 62 active moiety 62 DP b# 62 oral formulation 62 pharmacokinetics pharmacodynamics 62 decitabine 62 PF # [001] 62 Interferon alpha 62 Phase 2a trial 62 liposomal formulation 62 CANCIDAS 62 biodistribution 62 dose regimens 62 diabetic neuropathic pain 62 varespladib 62 SCH # 62 Traficet EN 62 INCB# [001] 62 Tolerability 62 XmAb# 61 fluticasone furoate 61 cannabinor 61 desvenlafaxine succinate 61 ISIS # 61 pharmacodynamic profiles 61 multiple ascending dose 61 bioavailability 61 Phase 1b 61 vidofludimus 61 JAK inhibitor 61 CYT# 61 GAMMAGARD 61 intravenously administered 61 PXD# 61 PS# [001] 61 MIRCERA 61 selective modulator 61 Laquinimod 61 dose escalation study 61 CG# [003] 61 LY# [003] 61 CCX# 61 antitumor effects 61 PSN# [002] 61 Bezielle 61 oral rivaroxaban 61 prodrug 61 intermittent dosing 61 Preclinical studies 61 Phase 2b study 61 anticancer activity 61 pharmacokinetic studies 61 pitavastatin 61 Vidofludimus 61 #mg dose [003] 61 Archexin 61 tezampanel 61 dexpramipexole 61 posaconazole 61 preclinical efficacy 61 allopurinol 61 Zoraxel 61 Phase Ib study 61 prucalopride 61 Aclidinium 61 ritonavir boosted 60 CaPre TM 60 dose proportionality 60 CoFactor 60 LEVADEX 60 Posiphen 60 apremilast 60 urocortin 2 60 solithromycin 60 R#/MEM # 60 Tyrima 60 Phase 1a 60 vorinostat 60 Dasatinib 60 TG# [003] 60 Omacetaxine mepesuccinate 60 dose proportional pharmacokinetics 60 INT# [002] 60 alagebrium 60 plasma kallikrein inhibitor 60 dosing schedules 60 melphalan prednisone 60 Phase IIa trial 60 orally dosed 60 bendamustine 60 pharmacokinetic equivalence 60 TRIOLEX 60 Pharmacokinetics PK 60 chlorambucil 60 VA# [002] 60 AZILECT R 60 INCB# [002] 60 Debio 60 MAP# 60 Pharmacokinetic 60 PMX # 60 antitumor effect 60 pomalidomide 60 fosbretabulin 60 investigational compound 60 VAPRISOL 60 partial agonist 60 anti amnesic 60 BAL# [002] 60 davunetide intranasal AL 60 IFN alpha 60 angiogenesis inhibitor 60 safety tolerability pharmacodynamics 59 CA4P 59 enzastaurin 59 nucleoside analog 59 double blinded placebo 59 beclomethasone dipropionate 59 dosing frequency 59 serum concentrations 59 RLY# 59 ascending dose 59 dosage regimen 59 insulin lispro 59 anticancer agent 59 IFN beta 59 APTIVUS 59 Zerenex 59 rNAPc2 59 orally administered 59 DU #b 59 preclinical studies 59 PEG Interferon lambda 59 anti angiogenic 59 mapatumumab 59 Inhalation Solution 59 GRN#L 59 CTA# 59 Phase Ib 59 Ophena TM 59 LSI #P 59 pharmacokinetic PK study 59 torezolid phosphate 59 Carfilzomib 59 pertuzumab 59 Serdaxin 59 LIALDA 59 hour bronchodilation 59 Pharmacokinetic studies 59 APOPTONE 59 ARRY 59 LEXIVA r 59 tiotropium 59 noninferiority 59 inhaled iloprost 59 dosed orally 59 nebulized formoterol fumarate 59 MoxDuo ® IR 59 intravenous dosing 59 MGd 59 Phase Ib clinical 59 eniluracil 59 glucose lowering 59 bosentan 59 Imprime PGG 59 Androxal TM 59 riociguat 59 systemic absorption 59 paricalcitol 59 hyperphenylalaninemia HPA due 59 LEXIVA 59 Phase IIa clinical 59 huN# DM1 59 Apoptone 59 TRV# [001] 59 IMGN# 59 Xanafide 59 placebo controlled clinical 59 elagolix 59 dose escalation 59 protease inhibitor PI 59 #mg BID [003] 59 tecarfarin 59 optimal dosing 59 antithrombotic 59 telaprevir dosed 59 Phase Ia 59 insulin degludec 59 coadministration 59 olmesartan 59 tipranavir 59 parathyroid hormone PTH 59 Protelos 59 dosing cohort 59 idraparinux 59 Preclinical studies suggest 59 pan HDAC inhibitor 59 adalimumab 59 eltrombopag 59 JANUVIA 59 cardiac toxicity 59 caspofungin 59 Dual Opioid 59 calcitonin 59 L PPDS 59 plasma pharmacokinetics 59 serotonin norepinephrine reuptake inhibitor 59 immunogenic 59 PI3K inhibitor 59 obatoclax 59 Chemophase 59 octreotide 59 ADAGIO study 59 pegfilgrastim 58 PEG PAL 58 plasma uric acid 58 novel prodrug 58 clinically meaningful efficacy 58 ALGRX 58 serum phosphorus 58 tolerability pharmacokinetics 58 GATTEX 58 LEP ETU 58 RSD# 58 azacitidine 58 ganetespib 58 vandetanib 58 BAY #-# 58 histone deacetylase HDAC inhibitor 58 RG# [001] 58 PROMACTA 58 QD dosing 58 Phase 2b trial 58 tablet formulation 58 efficacy endpoint 58 irbesartan 58 vascular disrupting agent 58 AIR# [001] 58 tapentadol ER 58 dose regimen 58 salmeterol fluticasone 58 oral FTY# 58 bronchodilator 58 Menerba 58 MoxDuo IR 58 vivo potency 58 generation purine nucleoside 58 lisdexamfetamine dimesylate 58 monotherapy 58 viral kinetics 58 novel histone deacetylase 58 ZOLINZA 58 highly immunogenic 58 pharmacokinetic interactions 58 ULORIC 58 long acting muscarinic 58 indibulin 58 subcutaneously injected 58 Etoposide 58 NPH insulin 58 mTOR inhibitors 58 angiotensin receptor blocker ARB 58 anticancer compound 58 HCV protease 58 Phase IIa 58 potent antiviral 58 resolvin 58 APRISO 58 Pharmacokinetic PK 58 Tasimelteon 58 PEG SN# 58 lanthanum carbonate 58 ritonavir boosting 58 DAVANAT 58 otelixizumab 58 guanfacine 58 intravesical 58 Dapagliflozin 58 azilsartan medoxomil 58 non nucleoside 58 APTIVUS r 58 mg doses 58 platelet inhibitor 58 lispro 58 CIMZIA ™ 58 SNRI 58 nab paclitaxel 58 Zysolin TM 58 sitagliptin 58 mecamylamine 58 USL# 58 lacosamide 58 ibandronate 58 candesartan cilexetil 58 phase IIa clinical 58 retapamulin 58 tasimelteon 58 mertansine 58 axitinib 58 CorVue ™ 58 BNC# 58 Anticalins 58 DB# [003] 58 AEGR 58 double blind placebo 58 glucocorticoid 58 S/GSK# 58 acting muscarinic antagonist 58 ISENTRESS 58 mg QD 58 daunorubicin 58 granisetron 58 zileuton 58 LT NS# 58 fluvastatin 58 Phase 2a clinical 58 Belerofon 58 KAPIDEX 58 sublingual formulation 58 virologic response 58 PDE4 inhibitor 58 neurologic progression 58 HGS ETR1 58 ALVESCO 58 subcutaneous injections 58 AAG geldanamycin analog 58 selective inhibitor 58 tiotropium bromide 58 systemic bioavailability 58 NU# [001] 58 MoxDuo 58 orally administered inhibitor 58 Pimavanserin 58 HIF PHI 58 calcitriol 58 hGH CTP 58 Synavive 58 phase IIb clinical 58 sorafenib Nexavar 58 immunomodulator 58 mealtime insulin 58 Tezampanel 58 docetaxel Taxotere R 57 Epanova 57 ruxolitinib 57 paclitaxel poliglumex 57 MabCampath 57 ARIKACE 57 vitro cytotoxicity 57 ataluren 57 HGS# 57 visilizumab 57 secondary efficacy endpoints 57 GHRH 57 selective antagonist 57 depsipeptide 57 LDL lowering 57 ISTODAX 57 IMC A# 57 forodesine 57 Seliciclib 57 Onconase 57 biologic therapy 57 aprepitant 57 phase Ib 57 gastric pH 57 demonstrated antitumor activity 57 achieved statistical significance 57 Plicera 57 Zoraxel TM 57 immunomodulatory therapy 57 tobramycin 57 investigational drug 57 GAMMAGARD LIQUID 57 trabectedin 57 Q#IR 57 docetaxel chemotherapy 57 XP# Transported Prodrug 57 virus HCV protease inhibitor 57 amrubicin 57 selegiline 57 LCP Tacro 57 Melphalan 57 KRN# 57 oral deforolimus 57 COPEGUS 57 HuLuc# 57 placebo controlled 57 Panzem R 57 Durezol 57 alefacept 57 effector function 57 synthetic peptide 57 Amrubicin 57 Blinatumomab 57 ramelteon 57 HuMax CD# 57 vitro potency 57 elacytarabine 57 Symadex 57 HGS ETR2 57 latanoprost 57 AEG# 57 eculizumab 57 efficacy endpoints 57 mg BID 57 veltuzumab 57 IPX# 57 FOSRENOL R 57 LDL cholesterol lowering 57 cytotoxicity 57 docetaxel Taxotere ® 57 CLORETAZINE TM VNP#M 57 IFN α 57 inecalcitol 57 anti EGFR antibody 57 antidepressant efficacy 57 GnRH antagonist 57 viral kinetic 57 6R BH4 57 LHRH antagonists 57 Ceplene/IL-2 57 nitazoxanide 57 ARCOXIA 57 potency selectivity 57 pharmacokinetic pharmacodynamic 57 nonclinical studies 57 retinoid 57 NP2 Enkephalin 57 inhibitor RG# 57 elotuzumab 57 metaglidasen 57 TriRima 57 velafermin belinostat 57 synthetic progestin 57 RSD# oral 57 plasma renin activity 57 abacavir lamivudine 57 bevirimat 57 Hsp# inhibitor 57 CTCE 57 intravitreal injection 57 COPAXONE R 57 Empatic 57 metreleptin 57 cariprazine 57 pramipexole 57 Perforomist ™ Inhalation Solution 57 injectable formulation 57 TOLAMBA 57 Welchol 57 serum cholesterol 57 insulin detemir 57 esomeprazole 57 ofatumumab 57 TMC# [002] 57 selective kinase inhibitor 57 fulvestrant 57 budesonide 57 histone deacetylase inhibitor 57 PRX# 57 NOX E# 57 inhibitory effects 57 chemotherapeutic drug 57 CXB# 57 ketorolac 57 daily subcutaneous injections 57 GLP1 agonist 57 FTY# 57 Phase 1a clinical 57 xenograft models 57 sodium glucose cotransporter 57 novel VDA molecule 57 pharmacodynamic markers 57 alvespimycin 57 LCP AtorFen 57 Dabigatran etexilate 57 glatiramer acetate 57 Marqibo 57 timolol 57 selective agonist 57 lintuzumab 57 MGCD# [001] 57 RAPAFLO 57 mycophenolate mofetil 57 convenient dosing regimens 57 interferon alfa 57 HIF PH inhibitors 57 PPAR gamma agonist 57 #ME# 57 #I TM# 57 bortezomib 57 cangrelor 57 HuMax EGFr 57 Valortim 57 mTOR inhibitor 57 oral anticoagulant 57 inhaled corticosteroid ICS 57 trodusquemine 57 Phase 2a 57 EMBEDA ™ 57 ALB # 57 EOquin TM 57 EOquin 57 thymalfasin 56 Phase #b/#a trial 56 amphotericin B 56 topical formulation 56 PYY 56 reactogenicity 56 MEK inhibitors 56 selectively inhibits 56 OXi# 56 phase IIb study 56 receptor antagonist 56 ZD# [001] 56 neuroprotective effects 56 pramlintide 56 interferon alfa 2b 56 incretin 56 pioglitazone HCl 56 AZILECT ® 56 bile acid sequestrant 56 inhaled formulation 56 ZYBRESTAT 56 beta2 agonist 56 treprostinil 56 interferon beta 56 receptor antagonists 56 Prograf ® 56 Forodesine HCl 56 serum cortisol 56 galiximab 56 ciclesonide 56 clinical trials Multikine 56 R baclofen 56 SPRYCEL 56 peginterferon alfa 2a 56 Capesaris 56 DLTs 56 erlotinib Tarceva ® 56 nucleotide analog 56 5 FU 56 INC# 56 lomitapide 56 mg kg dose 56 peripherally acting 56 clinically meaningful 56 fluticasone salmeterol 56 Phase Ib II 56 TNF alpha inhibitor 56 formoterol fumarate 56 non inferiority 56 fondaparinux 56 KB# [002] 56 INGN 56 oral ridaforolimus 56 Exenatide 56 vapreotide acetate 56 HZT 56 NEUGENE antisense 56 REMINYL ® 56 Bendavia 56 FOSRENOL ® 56 octreotide acetate 56 deferiprone 56 Targretin 56 dalbavancin 56 peginterferon alfa 2b 56 Nasulin 56 docetaxel 56 CRx 56 omega interferon 56 bactericidal activity 56 dosed 56 heavily pretreated 56 tipifarnib 56 radezolid 56 aclidinium 56 xanthine oxidase inhibitor 56 gemcitabine cisplatin 56 CONCERTA 56 uric acid lowering 56 Teriflunomide 56 D aspartate NMDA receptor 56 JVRS 56 cardioprotective effects 56 nelfinavir 56 evaluating tivozanib 56 RH1 56 LANTUS R 56 analgesic 56 Pegasys ® 56 DCCR 56 PREZISTA r 56 Genz # 56 cinacalcet 56 Privigen 56 adalimumab Humira 56 intranasal formulation 56 antitumor 56 Solulin 56 dose cohort 56 antibody titers 56 Androxal 56 leucovorin 56 AZD# 56 RoACTEMRA 56 sapacitabine 56 corticosteroid dexamethasone 56 C1 INH 56 TNF inhibitor 56 uricase 56 vicriviroc 56 dose ritonavir 56 TRO# 56 low dose ritonavir 56 trospium 56 HspE7 56 peak plasma concentrations 56 placebo controlled clinical trials 56 ACTEMRA 56 oral diclofenac 56 urate lowering 56 clinical trials alitretinoin 56 pressor response 56 placebo controlled randomized 56 subcutaneous dose 56 PCK# 56 somatostatin analogue 56 etanercept 56 montelukast 56 DermaVir Patch 56 MEK inhibitor 56 FTY# fingolimod 56 NeuroSTAT ® 56 CYCLOSET 56 IMA# 56 SPC# [001] 56 Vaprisol 56 steroid dexamethasone 56 Tarceva TM 56 randomized Phase III 56 deforolimus 56 Phenoptin 56 anti androgen 56 kinase inhibitor 56 Phase IIb clinical 56 #mg ritonavir 56 μg dose 56 echinocandin 56 ATACAND 56 bicifadine 56 Amigal 56 topotecan 56 Tamibarotene 56 placebo controlled studies 56 MICARDIS ® 56 aliskiren 56 Phase 1b clinical 56 imetelstat 56 ancrod 56 rosuvastatin #mg 56 Darusentan 56 oral gallium 56 ranolazine 56 itraconazole 56 raltegravir 56 antiangiogenic activity 56 imatinib therapy 56 protease inhibitor 56 plus prednisone 56 vWF 56 CYC# 56 receptor inhibitor 56 glargine 56 Omacetaxine 56 EZN 56 mesalamine granules 56 sunitinib 56 IV bolus 56 primary hypercholesterolemia 56 tocilizumab 56 regorafenib 56 tacrolimus 56 5 HT2C receptor 56 alkylating agent 56 Vidaza azacitidine 56 FOLPI 56 BENICAR HCT 56 intramuscular 56 plus dexamethasone 56 Pharmacokinetic parameters 56 topically administered 56 ocular formulation 56 factor Xa inhibitor 56 delafloxacin 56 Oral NKTR 56 antisense drug 56 EFAPROXYN 56 SPIRIVA HandiHaler 56 Panzem R NCD 56 belinostat 56 piperacillin tazobactam 56 ACTEMRA TM 56 Plenaxis TM 56 SERCA2a 56 IPLEX 56 proton pump inhibitor PPI 56 brivaracetam 56 methylnaltrexone 56 plasma kallikrein 56 EQUETRO 56 TH# [003] 56 surrogate endpoint 56 AZOR 56 boosted protease inhibitor 56 mg TID 56 dose escalation Phase 56 receptor blocker 56 #beta estradiol 56 radiolabeled 56 HSP# inhibitor 56 Amplimexon 56 Zenvia 56 sirolimus 56 administered intranasally 56 Multimeric 56 MAGE A3 ASCI 56 Vilazodone 56 CTAP# Capsules 56 gonadotrophin releasing hormone GnRH 56 GORE VIABAHN Endoprosthesis 56 dasatinib 56 Degarelix 55 injectable formulations 55 elvitegravir 55 linear pharmacokinetics 55 IDX# 55 ganciclovir 55 placebo controlled Phase 55 Anticalins ® 55 potent inhibitor 55 prospectively defined 55 RE SURGE 55 mu opioid receptor antagonist 55 Anthim 55 erythropoietic 55 selective adenosine 55 Keppra XR 55 Epoetin alfa 55 MB# [004] 55 8mg/kg 55 HMG CoA reductase inhibitors 55 CRESTOR #mg 55 CR# vcMMAE 55 serum phosphate levels 55 Rebif ® 55 anti angiogenic agent 55 NOXAFIL Oral Suspension 55 alvimopan 55 fosamprenavir 55 VPRIV 55 dosing interval 55 dexamethasone Decadron 55 bioequivalent 55 Excellarate 55 Engerix B 55 immune modulating 55 HDAC inhibitor 55 INCB# [003] 55 zonisamide SR 55 Adalimumab 55 DuraSite 55 AKT inhibitor 55 subcutaneous dosing 55 SYMBICORT 55 lead Aganocide compound 55 PRX # 55 neurotoxicity 55 cidofovir 55 Perforomist TM Inhalation Solution 55 epoetin alfa 55 Cotara 55 vivo efficacy 55 levetiracetam 55 TMC# [001] 55 certolizumab 55 OMNARIS HFA 55 mesalamine 55 ROZEREM TM 55 milatuzumab 55 risedronate 55 HQK 55 CCR9 antagonist 55 renal function 55 Temozolomide 55 darunavir ritonavir 55 Vfend 55 postprandial glycemia 55 Tolvaptan 55 inhibitory effect 55 MP4OX 55 ELACYT 55 AZILECT 55 BMS# 55 KL4 surfactant 55 YONDELIS 55 tolvaptan 55 XL# [003] 55 indacaterol 55 pharmacologically active isomer 55 somatostatin analog 55 ApoA1 55 seliciclib 55 ProSavin 55 RG# ITMN 55 MNTX 55 relapsing remitting multiple sclerosis 55 temozolomide 55 balsalazide 55 diabetic gastroparesis 55 ARIKACE ™ 55 huC# DM4 55 PSMA ADC 55 atazanavir ritonavir 55 cilengitide 55 pharmacologic 55 adipiplon 55 proteasome inhibitors 55 sulodexide 55 GLP toxicology studies 55 lucinactant 55 Telmisartan 55 Nanobody 55 phase 2a 55 Golimumab 55 PEGylated anti 55 lopinavir r 55 Cloretazine 55 atacicept 55 docetaxel Taxotere 55 rotigotine 55 arbaclofen 55 basal insulin 55 KSP inhibitor 55 bioactivity 55 albiglutide 55 teriparatide 55 laropiprant 55 CORT # 55 tamsulosin 55 Pemetrexed 55 Clolar 55 factor Xa 55 calcipotriene 55 pimecrolimus 55 Genasense ® oblimersen 55 Bronchitol 55 GLPG# 55 preclinical models 55 aripiprazole 55 ALKS 55 PREOS 55 inhibit platelet aggregation 55 pegylated liposomal doxorubicin 55 Aeroquin 55 pharmacodynamic endpoints 55 MoxDuo ® 55 nanomolar range 55 oral antidiabetic 55 ILLUMINATE 55 angiotensin II receptor blocker 55 tapentadol IR 55 6mg 55 gastrointestinal motility 55 PEGylated interferon beta 1a 55 PTHrP 55 CBLC# 55 IRX 2 55 oral renin inhibitor 55 dose colchicine 55 lipid parameters 55 Tracleer R 55 antitumor efficacy 55 oral dosing regimen 55 nanomolar 55 zonisamide 55 capsule formulation 55 highly selective inhibitor 55 Pharmacokinetics 55 μg kg 55 Antiviral Activity 55 ON #.Na 55 ESBA# 55 intracellular uptake 55 BENICAR 55 PKC# 55 cobiprostone 55 cytoprotective 55 gemcitabine Gemzar 55 Phase Ib clinical trials 55 Pharmacokinetic analyzes 55 Neurodex 55 platelet inhibition 55 CK # 55 low dose cytarabine 55 nicardipine 55 lurasidone 55 Gleevec resistant 55 safinamide 55 anti proliferative 55 etoposide